CuraTeQ Biologics receives positive opinion for biosimilar Zefylti
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
The trademark rights for these brands will be transferred to Lupin by March next year.
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
First and only PARP inhibitor to improve overall survival in early breast cancer
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Subscribe To Our Newsletter & Stay Updated